Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 2180417, 8 pages
http://dx.doi.org/10.1155/2016/2180417
Review Article

Holding the Inflammatory System in Check: TLRs and Their Targeted Therapy in Asthma

1Department of Pathogen Biology, Basic Medical College, Jilin University, Changchun 130021, China
2Department of Respiratory Disease, Jilin Provincial People’s Hospital, Changchun 130021, China
3Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW 2305, Australia

Received 24 February 2016; Accepted 13 April 2016

Academic Editor: Eda Holl

Copyright © 2016 Zhiyong Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Medzhitov, “Origin and physiological roles of inflammation,” Nature, vol. 454, no. 7203, pp. 428–435, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. K. F. Chung, “Targeting the interleukin pathway in the treatment of asthma,” The Lancet, vol. 386, no. 9998, pp. 1086–1096, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Accordini, A. G. Corsico, M. Braggion et al., “The cost of persistent asthma in Europe: an international population-based study in adults,” International Archives of Allergy and Applied Immunology, vol. 160, no. 1, pp. 93–101, 2013. View at Google Scholar
  5. S. Phipps, C. E. Lam, P. S. Foster, and K. I. Matthaei, “The contribution of toll-like receptors to the pathogenesis of asthma,” Immunology and Cell Biology, vol. 85, no. 6, pp. 463–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Goulopoulou, C. G. McCarthy, and R. C. Webb, “Toll-like receptors in the vascular system: sensing the dangers within,” Pharmacological Reviews, vol. 68, no. 1, pp. 142–167, 2016. View at Publisher · View at Google Scholar
  7. J. Jang, H. W. Shin, J. M. Lee, H. Lee, E. Kim, and S. H. Park, “An overview of pathogen recognition receptors for innate immunity in dental pulp,” Mediators of Inflammation, vol. 2015, Article ID 794143, 12 pages, 2015. View at Publisher · View at Google Scholar
  8. L. Zuo, K. Lucas, C. A. Fortuna, C. Chuang, and T. M. Best, “Molecular regulation of toll-like receptors in asthma and COPD,” Frontiers in Physiology, vol. 6, article 312, 2015. View at Publisher · View at Google Scholar
  9. V. Piras and K. Selvarajoo, “Beyond MyD88 and TRIF pathways in Toll-like receptor signaling,” Frontiers in Immunology, vol. 5, article 70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. K. B. Narayanan and H. H. Park, “Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways,” Apoptosis, vol. 20, no. 2, pp. 196–209, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Lee, L. C. Wang, H. H. Yu, Y. T. Lin, Y. H. Yang, and B. L. Chiang, “Type I IL-1 receptor (IL-1RI) as potential new therapeutic target for bronchial asthma,” Mediators of Inflammation, vol. 2010, Article ID 567351, 7 pages, 2010. View at Publisher · View at Google Scholar
  12. T. Kawai, O. Adachi, T. Ogawa, K. Takeda, and S. Akira, “Unresponsiveness of MyD88-deficient mice to endotoxin,” Immunity, vol. 11, no. 1, pp. 115–122, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Takeuchi, K. Takeda, K. Hoshino, O. Adachi, T. Ogawa, and S. Akira, “Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades,” International Immunology, vol. 12, no. 1, pp. 113–117, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Häcker, R. M. Vabulas, O. Takeuchi, K. Hoshino, S. Akira, and H. Wagner, “Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6,” The Journal of Experimental Medicine, vol. 192, no. 4, pp. 595–600, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Hayashi, K. D. Smith, A. Ozinsky et al., “The innate immune response to bacterial flagellin is mediated by Toll-like receptor-5,” Nature, vol. 410, no. 6832, pp. 1099–1103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Hemmi, T. Kaisho, O. Takeuchi et al., “Small-antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway,” Nature Immunology, vol. 3, no. 2, pp. 196–200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Yamamoto, S. Sato, H. Hemmi et al., “Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway,” Science, vol. 301, no. 5633, pp. 640–643, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Hoebe, X. Du, P. Georgel et al., “Identification of Lps2 as a key transducer of MyD88-independent TIR signalling,” Nature, vol. 424, no. 6950, pp. 743–748, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. Global Initiative for Asthma, “GINA report, Global Stragety for Asthma Management and Prevention,” Documents/Resources, GINA, April 2015, http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf.
  20. F. Wang, X. Y. He, K. J. Baines et al., “Different inflammatory phenotypes in adults and children with acute asthma,” European Respiratory Journal, vol. 38, no. 3, pp. 567–574, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Agusti, E. Bel, M. Thomas et al., “Treatable traits: toward precision medicine of chronic airway diseases,” European Respiratory Journal, vol. 47, no. 2, pp. 410–419, 2016. View at Publisher · View at Google Scholar
  22. M. W. Pijnenburg and S. Szefler, “Personalized medicine in children with asthma,” Paediatric Respiratory Reviews, vol. 16, no. 2, pp. 101–107, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. K. M. Kew and K. Dahri, “Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD011721, 2016. View at Publisher · View at Google Scholar
  24. J. B. Bice, E. Leechawengwongs, and A. Montanaro, “Biologic targeted therapy in allergic asthma,” Annals of Allergy, Asthma and Immunology, vol. 112, no. 2, pp. 108–115, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. J. L. Simpson, T. V. Grissell, J. Douwes, R. J. Scott, M. J. Boyle, and P. G. Gibson, “Innate immune activation in neutrophilic asthma and bronchiectasis,” Thorax, vol. 62, no. 3, pp. 211–218, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A.-K. Ekman, M. Adner, and L.-O. Cardell, “Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle,” European Journal of Pharmacology, vol. 652, no. 1–3, pp. 145–151, 2011. View at Publisher · View at Google Scholar
  27. I. Ioannidis, F. Ye, B. McNally, M. Willette, and E. Flaño, “Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells,” Journal of Virology, vol. 87, no. 6, pp. 3261–3270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. G. Drake, E. H. Kaufman, A. D. Fryer, and D. B. Jacoby, “The therapeutic potential of Toll-like receptor 7 stimulation in asthma,” Inflammation & Allergy—Drug Targets, vol. 11, no. 6, pp. 484–491, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. T. Holgate, G. Roberts, H. S. Arshad, P. H. Howarth, and D. E. Davies, “The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis,” Proceedings of the American Thoracic Society, vol. 6, no. 8, pp. 655–659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Hatchwell, A. Collison, J. Girkin et al., “Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia,” Thorax, vol. 70, no. 9, pp. 854–861, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Duechs, C. Hahn, E. Benediktus et al., “TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways,” Pulmonary Pharmacology and Therapeutics, vol. 24, no. 2, pp. 203–214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Meng, X. He, W. Zhu et al., “TLR3 and TLR7 modulate IgE production in antigen induced pulmonary inflammation via influencing IL-4 expression in immune organs,” PLoS ONE, vol. 6, no. 2, Article ID e17252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Frotscher, K. Anton, and M. Worm, “Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors,” Journal of Investigative Dermatology, vol. 119, no. 5, pp. 1059–1064, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Shen, L. Lu, and C. Wu, “TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes,” Scandinavian Journal of Immunology, vol. 67, no. 6, pp. 560–568, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Brugnolo, S. Sampognaro, F. Liotta et al., “The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-γ-producing cells,” Journal of Allergy and Clinical Immunology, vol. 111, no. 2, pp. 380–388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Wills-Karp, J. Luyimbazi, X. Xu et al., “Interleukin-13: central mediator of allergic asthma,” Science, vol. 282, no. 5397, pp. 2258–2261, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Grela, A. Aumeunier, E. Bardel et al., “The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-γ,” The Journal of Immunology, vol. 186, no. 1, pp. 284–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. Q. Du, L.-F. Zhou, Z. Chen, X.-Y. Gu, M. Huang, and K.-S. Yin, “Imiquimod, a toll-like receptor 7 ligand, inhibits airway remodelling in a murine model of chronic asthma,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 1, pp. 43–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Camateros, M. Tamaoka, M. Hassan et al., “Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463,” American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 12, pp. 1241–1249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S. W. Lee, D. R. Kim, T. J. Kim et al., “The association of down-regulated toll-like receptor 4 expression with airflow limitation and emphysema in smokers,” Respiratory Research, vol. 13, article106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Werner, R. Topp, K. Wimmer et al., “TLR4 gene variants modify endotoxin effects on asthma,” Journal of Allergy and Clinical Immunology, vol. 112, no. 2, pp. 323–330, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. Q. Zhang, F. H. Qian, L. F. Zhou et al., “Polymorphisms in toll-like receptor 4 gene are associated with asthma severity but not susceptibility in a Chinese Han population,” Journal of Investigational Allergology and Clinical Immunology, vol. 21, no. 5, pp. 370–377, 2011. View at Google Scholar
  43. K. Tizaoui, W. Kaabachi, K. Hamzaoui, and A. Hamzaoui, “Association of single nucleotide polymorphisms in Toll-like receptor genes with asthma risk: a systematic review and meta-analysis,” Allergy, Asthma & Immunology Research, vol. 7, no. 2, pp. 130–140, 2015. View at Publisher · View at Google Scholar
  44. E. M. M. Klaassen, B. E. J. T. Thönissen, G. van Eys, E. Dompeling, and Q. Jöbsis, “A systematic review of CD14 and toll-like receptors in relation to asthma in Caucasian children,” Allergy, Asthma and Clinical Immunology, vol. 9, article 10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. F. H. Qian, Q. Zhang, L. F. Zhou, G. F. Jin, J. L. Bai, and K. S. Yin, “Polymorphisms in the toll-like receptor2 subfamily and risk of asthma: a case-control analysis in a Chinese population,” Journal of Investigational Allergology and Clinical Immunology, vol. 20, no. 4, pp. 340–346, 2010. View at Google Scholar
  46. A. Heinzmann, M. Brugger, S. Bierbaum, B. Mailaparambil, M. V. Kopp, and K. Strauch, “Joint influences of Acidic-Mammalian-Chitinase with Interleukin-4 and Toll-like receptor-10 with Interleukin-13 in the genetics of asthma,” Pediatric Allergy and Immunology, vol. 21, no. 4, part 2, pp. e679–e686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Lazarus, W. T. Klimecki, B. A. Raby et al., “Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies,” Genomics, vol. 81, no. 1, pp. 85–91, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. M. S. D. Kormann, M. Depner, D. Hartl et al., “Toll-like receptor heterodimer variants protect from childhood asthma,” Journal of Allergy and Clinical Immunology, vol. 122, no. 1, pp. 86–e8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. T. V. Grissell, H. Powell, D. R. Shafren et al., “Interleukin-10 gene expression in acute virus-induced asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 4, pp. 433–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. P. A. B. Wark, S. L. Johnston, I. Moric, J. L. Simpson, M. J. Hensley, and P. G. Gibson, “Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma,” European Respiratory Journal, vol. 19, no. 1, pp. 68–75, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Rupani, R. T. Martinez-Nunez, P. Dennison et al., “Toll-like receptor 7 is reduced in severe asthma and linked to altered microRNA profile,” American Journal of Respiratory and Critical Care Medicine, 2016. View at Publisher · View at Google Scholar
  52. M. Contoli, S. D. Message, V. Laza-Stanca et al., “Role of deficient type III interferon-λ production in asthma exacerbations,” Nature Medicine, vol. 12, no. 9, pp. 1023–1026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Sykes, M. R. Edwards, J. MacIntyre et al., “Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients,” Journal of Allergy and Clinical Immunology, vol. 129, no. 6, pp. 1506–1514, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. A. L. Pritchard, O. J. White, J. G. Burel, M. L. Carroll, S. Phipps, and J. W. Upham, “Asthma is associated with multiple alterations in anti-viral innate signalling pathways,” PLoS ONE, vol. 9, no. 9, Article ID e106501, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Matsumoto, H. Oshiumi, and T. Seya, “Antiviral responses induced by the TLR3 pathway,” Reviews in Medical Virology, vol. 21, no. 2, pp. 67–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. K. S. Parsons, A. C. Hsu, and P. A. B. Wark, “TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection,” Clinical and Experimental Allergy, vol. 44, no. 1, pp. 91–101, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. R. H. Xu, E. B. Wong, D. Rubio et al., “Sequential activation of two pathogen-sensing pathways required for Type I interferon expression and resistance to an acute DNA virus infection,” Immunity, vol. 43, no. 6, pp. 1148–1159, 2015. View at Publisher · View at Google Scholar
  58. D. Tworek, S. G. Smith, B. M. Salter et al., “Interleukin 25 receptor expression on airway dendritic cells after allergen challenge in asthmatic subjects,” American Journal of Respiratory and Critical Care Medicine, 2015. View at Publisher · View at Google Scholar
  59. M. J. Duechs, C. Tilp, C. Tomsic, F. Gantner, and K. J. Erb, “Development of a novel severe triple allergen asthma model in mice which is resistant to dexamethasone and partially resistant to TLR7 and TLR9 agonist treatment,” PLoS ONE, vol. 9, no. 3, Article ID e91223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. J. N. Kline, T. J. Waldschmidt, T. R. Businga et al., “Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma,” The Journal of Immunology, vol. 160, no. 6, pp. 2555–2559, 1998. View at Google Scholar · View at Scopus
  61. A. Lhrmann, T. Tschernig, H. von der Leyen, M. Hecker, R. Pabst, and A. H. Wagner, “Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model,” Experimental Lung Research, vol. 36, no. 2, pp. 85–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. V. V. Jain, K. Kitagaki, T. Businga et al., “CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma,” Journal of Allergy and Clinical Immunology, vol. 110, no. 6, pp. 867–872, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Y. Lee, J. Y. Cho, M. Miller et al., “Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice,” Journal of Allergy and Clinical Immunology, vol. 117, no. 3, pp. 597–603, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. D.-J. Chiang, Y.-L. Ye, W.-L. Chen, Y.-L. Lee, N.-Y. Hsu, and B.-L. Chiang, “Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation,” American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 5, pp. 575–580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Ashino, D. Wakita, Y. Zhang, K. Chamoto, H. Kitamura, and T. Nishimura, “CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung,” International Immunology, vol. 20, no. 2, pp. 259–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Fedulov, E. Silverman, Y. Xiang, A. Leme, and L. Kobzik, “Immunostimulatory CpG oligonucleotides abrogate allergic susceptibility in a murine model of maternal asthma transmission,” The Journal of Immunology, vol. 175, no. 7, pp. 4292–4300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. Z. Aryan, S. T. Holgate, D. Radzioch, and N. Rezaei, “A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma,” International Archives of Allergy and Immunology, vol. 164, no. 1, pp. 46–63, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. C. M. Trujillo-Vargas, J. R. Ramirez-Pineda, A. Palmetshofer et al., “Mice vaccinated with allergen-pulsed myeloid dendritic cells are not protected from developing allergen-induced Th2 responses,” International Archives of Allergy and Immunology, vol. 137, no. 3, pp. 219–228, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Kapoor, L. Geng, A. Feldman, and H. Jyonouchi, “Characterization of severe asthma (SA) in children of inner-city of Newark: altered responses to recall antigens and a panel of agonists of Toll-like receptors (TLR),” Journal of Allergy and Clinical Immunology, vol. 127, article AB61, 2011. View at Google Scholar
  70. M. Tamm, D. H. Richards, B. Beghé, and L. Fabbri, “Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice,” Respiratory Medicine, vol. 106, no. 1, pp. S9–S19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. C. Xirakia, O. Koltsida, A. Stavropoulos et al., “Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 11, pp. 1207–1216, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Moisan, P. Camateros, T. Thuraisingam et al., “TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 290, no. 5, pp. L987–L995, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. D. Quarcoo, S. Weixler, R. A. Joachim et al., “Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice,” Clinical and Experimental Allergy, vol. 34, no. 8, pp. 1314–1320, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Ito, K. F. Chung, and I. M. Adcock, “Update on glucocorticoid action and resistance,” Journal of Allergy and Clinical Immunology, vol. 117, no. 3, pp. 522–543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. E. Chun, S.-H. Lee, S.-Y. Lee et al., “Toll-like receptor expression on peripheral blood mononuclear cells in asthmatics; implications for asthma management,” Journal of Clinical Immunology, vol. 30, no. 3, pp. 459–464, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. E. Pace, C. Di Sano, M. Ferraro et al., “Budesonide increases TLR4 and TLR2 expression in Treg lymphocytes of allergic asthmatics,” Pulmonary Pharmacology and Therapeutics, vol. 32, pp. 93–100, 2015. View at Publisher · View at Google Scholar · View at Scopus